Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar 27;17(3):105255.
doi: 10.4254/wjh.v17.i3.105255.

Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen

Vanessa Pamela Salolin Vargas  1 , Marisa Gasbarra  2 , Ernesto Calderon-Martinez  3 , Yash R Shah  4 , Dushyant Singh Dahiya  5 , Mauricio Garcia Saenz de Sicilia  6
Affiliations
Editorial

Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen

Vanessa Pamela Salolin Vargas et al. World J Hepatol. .

Abstract

In this editorial, we comment on the article by Zhao et al which highlighted how patients having nonalcoholic fatty liver disease (NAFLD) were more susceptible to drug-induced lung injury (DILI). This article looked at the downstream effects of metabolic profiles and biochemical processes after medication and substance use. Although previous studies looked at how NAFLD and DILI were related, there is a lack of information on the consequences of everyday medication and substance use. NAFLD is one of the most common chronic liver diseases worldwide and it has been found to be closely related to metabolic syndrome and cardiovascular disease. The aim of this editorial is to analyze the interaction between NAFLD and DILI, what clinical manifestations can occur and what the prognosis of these patients will be.

Keywords: Clinical characteristics; Drug-induced lung injury; Nonalcoholic fatty liver disease; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: We have no financial relationships to disclose.

Figures

Figure 1
Figure 1
The interactions between non-alcoholic fatty liver disease and drug use, focusing on three main pathways: Changes in cytochrome P450 enzymes, oxidative stress, and immunological responses. NAFLD: Non-alcoholic fatty liver disease; CYPs: Cytochrome P450 enzymes; ROS: Reactive oxygen species, IL-4: Interleukin-4; IgM: Immunoglobulin M; C3: Complement component 3.
See this image and copyright information in PMC

References

    1. Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168–e185. - PubMed
    1. Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond) 2016;16:s104–s109. - PMC - PubMed
    1. Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–1065. - PMC - PubMed
    1. Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, Xu J, Niu J, Liu J, Watkins PB, Aithal GP, Andrade RJ, Dou X, Yao L, Lv F, Wang Q, Li Y, Zhou X, Zhang Y, Zong P, Wan B, Zou Z, Yang D, Nie Y, Li D, Wang Y, Han X, Zhuang H, Mao Y, Chen C. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019;156:2230–2241.e11. - PubMed
    1. Liu YH, Guo Y, Xu H, Feng H, Chen DY. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist. 2021;14:3667–3671. - PMC - PubMed

Publication types

LinkOut - more resources